Valerie Bandy of Tecsys on where 340B rebate mechanics threaten pharmacy purchasing, and how stakeholders can prevent disruption. In the third and final installment of Pharmaceutical Commerce’s video ...
Leadership Summit will return to CPHI Milan, which runs Oct. 6-8 in Milan, Italy, as manufacturers face mounting pressu ...
The EU's pharma reform makes market protection more conditional. Here is how US drugmakers, especially startups, can adapt and use IP to complement it. The European Union's (EU) pharmaceutical reform ...
CMS says 40 states and Puerto Rico have signed on to the GENEROUS Model, which applies MFN pricing to Medicaid drugs through state-invoiced rebates. The Centers for Medicare & Medicaid Services (CMS) ...
DSCSA compliance is no longer a live question for most trading partners, but two new work streams, the shift to a 12-digit ...
In this week's Pharma Pulse, Arkansas independent pharmacies bring an underpayment suit against Express Scripts, Novo Nordisk ...
As pharmaceutical companies move AI into patient access and support operations, most still rely on manual sampling and ...
Manufacturer market-access teams should treat affiliate “data access” charges as contract risks unless services, deliverables, and FMV methodology are explicitly defined and documented. Geographic ...
In the final installment of his interview with Pharmaceutical Commerce, Cencora's Ameer Ali outlines how supply chain stakeholders should prepare systems, processes and trading partners for the shift ...
Liberty Dewey of Cardinal Health breaks down the NDC-12 transition timeline, the four work streams driving it and why the ...
Go behind the scenes of LogiPharma USA 2026 with program director Charleen Ring and McKesson's Chris Van Norman in this ...
Legislative paths for GENEROUS, GLOBE, and GUARD remain blocked by intra-party resistance and intensifying midterm dynamics, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results